Найти книгу: "Schizophrenia"

Schizophrenia is one of the most complex and disabling diseases to affect mankind. Relatively little is known about its nature and its origins, and available treatments are inadequate for most patients. As a result, there are inevitable controversies about what causes it, how to diagnose it, and how best to treat it. However, in the past decade, there has been an explosion of new research, with dramatic discoveries involving genetic etiology and epidemiological risk factors. There has also been a catalog of new drugs coming to market, and controversy about the relative advantages and disadvantages of newer compared with older therapies. In addition, developing technologies in genomics, molecular biology and neuroimaging provide streams of new information. This book represents a definitive, essential, and up-to-date reference text on schizophrenia. It extensively and critically digests and clarifies recent advances and places them within a clinical context. The Editors (one American and one British), highly respected clinical psychiatrists and researchers and acknowledged experts on schizophrenia, have again assembled an outstanding group of contributors from the USA, UK, Europe and Australia, It will be of value to practising psychiatrists and to trainees, as well as to clinical and neuroscience researchers interested in keeping up with this field or coming into it. The book consists of four sections: descriptive aspects, biological aspects, physical treatments, and psychological and social aspects. It reviews the theoretical controversies over symptomatology, classification and aetiology (particularly pertinent as DSM-V is being developed), the relationship of schizophrenia to the other psychoses, the significance of positive and negative symptoms and pre-morbid personality. It describes a variety of approaches to integrating the vast research data about schizophrenia, including neurodevelopmental, genetic, pharmacological, brain imaging and psychological findings. The biological treatment section reviews the comparative efficacy of various drugs, the management of drug-resistant patients and both neurological and metabolic complications. The final section looks at psychological therapies, social outcomes, and the economics of schizophrenia. Highly Commended in the Psychiatry section of the 2012 BMA Book Awards.

Для вас открывается вторая, параллельная психическая реальность, и ваша задача – удержать равновесие между внешним миром – объективной реальностью – и внутренним миром, реальностью мира вашей psyhe.

Книга является фантастическим рассказом, который повествует о нелёгкой судьбе главного героя – Мэтта. С течением некоторых обстоятельств у него развивается шизофрения. Она позволяет увидеть мир настоящим, и он понимает, что остальные видят лишь иллюзию реальности.

Practical tools for leading a happy, productive life Schizophrenia is a chronic, severe, and disabling mental disorder that afflicts one percent of the population, an estimated 2.5 million people in America alone. The firsthand advice in this reassuring guide will empower the families and caregivers of schizophrenia patients to take charge, offering expert advice on identifying the warning signs, choosing the right health professional, understanding currently available drugs and those on the horizon (as well as their side effects), and evaluating traditional and alternative therapies.

The first book in a new series from the World Psychiatric Association, Schizophrenia: current science and clinical practice presents recent information on the diagnosis, neurobiological foundations, and management of schizophrenia. It evaluates the findings obtained with modern techniques like magnetic resonance imaging, genetics and network analyses. The book reviews the importance of neurocognitive functioning in schizophrenia and its predictive value for functional capacity. It covers the key areas of early recognition, prevention, rehabilitation and stigma. There is also a critical discussion of diagnostic classification and the revision of the two major international systems. Written by experts in the field who have a track record of being engaging authors, this book provides a rapid overview of the current state of the art in schizophrenia research and clinical management. It will be invaluable to all psychiatrists, psychologists, neuropharmacologists, researchers in psychiatry and psychopharmacology in academia and in industry, and clinical and behavioural neuroscientists.

New and emerging directions in pharmaceutical research to better treat schizophrenia Although the dopamine hypothesis has been the cornerstone of schizophrenia therapeutics, it is clear that dopamine-based approaches do not treat all aspects of the disease. Moreover, many schizophrenia patients fail to respond to current antipsychotics. Integrating chemistry, biology, and pharmacology, this book explores emerging directions in pharmaceutical research for drug targeting and discovery in order to find more effective treatments for schizophrenia, one of the most serious and widespread psychiatric diseases. Targets and Emerging Therapies for Schizophrenia presents the basics of schizophrenia, drug targets for the disease, and potential new drugs and therapeutics. It begins with a discussion of prevalence and etiology. Then, it describes therapies such as dopamine agonists and phosphodiesterase (PDE) inhibitors as well as growing research aimed at addressing untreated symptoms. Next, the authors discuss receptor modulators, inhibitors, and targeting strategies for drug discovery. Both the neurobiological and chemical aspects of all major pharmacological targets are examined. With contributions from an international team of pioneering pharmaceutical researchers, this book compiles the current knowledge in the field, setting the stage for new breakthroughs in the treatment of schizophrenia. Targets and Emerging Therapies for Schizophrenia: Provides a comprehensive resource for neuro-drug discovery and the development of molecular targets for schizophrenia treatment Draws from chemistry, biology, and pharmacology for more effective drug targeting and discovery Explores a wide range of receptors and molecular targets, including dopamine, PDEs, and neuropeptides With Targets and Emerging Therapies for Schizophrenia as their guide, drug discovery and development scientists have the information they need to advance their own research so that new, more effective treatments for schizophrenia will soon be a reality.